Scholar Rock Holding Corporation Share Price & Technical Analysis
SRRK · $48.14 (+0.88%)
Healthcare / Biotechnology
$48.14
+0.88%
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of …
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
3% return in May, -19% avg return in past 3 year May month.
12% return in 2026, 123% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 1% | 0% | 14% | -7% | 3% | – | – | – | – | – | – | – | 12% |
| 25 | -6% | -2% | -17% | 3% | -12% | 22% | 5% | -11% | 13% | -20% | 50% | 0% | 26% |
| 24 | -25% | 10% | 15% | -16% | -36% | -14% | 10% | 2% | -13% | 259% | 39% | 6% | 238% |
| 23 | 32% | -29% | -7% | -23% | -9% | 27% | -7% | -13% | 13% | 66% | 7% | 49% | 106% |
| 22 | -28% | -3% | -25% | -46% | -30% | 10% | 28% | 22% | -17% | 38% | -20% | 15% | -57% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.79B
P/E ratio
—
52W high
$51.62
52W low
$27.07
Volume
4,65,771
Beta
0.71
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Scholar Rock Holding Corporation share price today?
- Scholar Rock Holding Corporation (SRRK) last traded around $48.14 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SRRK have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SRRK. Download the app for real-time alerts.
- How can I analyze Scholar Rock Holding Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.